AbbVie Inc. et al. v. Drew Wrigley, in his official capacity as the Attorney General of North Dakota, et al.; AstraZeneca Pharmaceuticals LP v. Drew Wrigley, in his official capacity as the Attorney General of North Dakota, et al.; Pharmaceutical Research and Manufacturers of America v. Drew Wrigley, in his official capacity as the Attorney General of North Dakota, et al.

Summary

The United States District Court for the District of North Dakota orders the parties in three consolidated pharmaceutical-industry cases to submit simultaneous supplemental briefing. The briefing must address standing, including enforcement and injury, and provide evidence concerning the effects and pharmacy-ownership structure of North Dakota’s prescription-drug system.

Questions Presented

1. Whether the plaintiffs have standing, including injury and any enforcement of the challenged statute after its July 1, 2025 effective date.
2. What additional North Dakota-specific evidence is needed to determine the challenged law's impact and whether North Dakota pharmacies act as agents for covered entities or retain title to medications.

Disposition

other